Lamassu BioTech

09/15/2025

Lamassu BioTech CEO Gabi Hanna MD. is featured on the Building Biotechs Podcast with Carina Clingman, PhD, highlighting the importance of accelerating drug development responsibly.

Acceleration is not about recklessness. It is about creativity and responsibility. Smarter trial design and fast, clear, and transparent engagement with the FDA can create new models that deliver therapies to patients faster and safer. Patients benefit most when knowledge flows responsibly, not slowly.

🎥 Full interview on YouTube: https://www.youtube.com/watch?v=ob86ZAszc-s

09/12/2025

Every day we delay, patients suffer. In the U.S. alone, 50 people die daily from acute pancreatitis, and hundreds more live with permanent complications. At Lamassu, we believe bringing treatments to patients faster isn’t just innovation, it’s a moral duty. When we align science, safety, and urgency, we save lives.



🎥 Full interview with Carina Clingman, PhD: https://www.youtube.com/watch?v=ob86ZAszc-s

09/10/2025

At this week’s 14th annual Summit in , Lamassu a MD., took part in an thought-provoking panel discussion about how incorporating the full spectrum of patient data can improve clinical outcomes and support predictive analysis.

Along with the panel discussion, Dr. Hanna had productive discussions with King Faisal Specialist Hospital & Research Centre Björn Zoega, and Ambassador Dr. Deborah Birx, the CEO of Armata Pharmaceuticals, Inc. and the former response coordinator for the White House Coronavirus Task Force under President Trump, among other dignitaries. C3 International’s summits continue do a tremendous job bolstering between the US and the Arab world to improve the future of healthcare.

09/03/2025

Season three of the Building Biotechs Podcast with Carina Clingman, PhD, kicks off today with Lamassu Biotech CEO Gabi Hanna MD. Dr. Hanna shared his thoughts on why an entrepreneurial mindset can be a benefit in an industry that typically follows a traditional development model, the patient-centric mission of Lamassu Biotech, as well as the moral imperative to accelerate drug development when combatting rare diseases. Click the link below to listen now to this exciting episode of the Building Biotechs Podcast.

For our first episode of season three, I sat down with Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech, where he leads the development of innovative t...

08/20/2025

🎙 𝐒𝐚𝐯𝐢𝐧𝐠 𝐋𝐢𝐯𝐞𝐬 𝐓𝐡𝐫𝐨𝐮𝐠𝐡 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: 𝐃𝐫. 𝐆𝐚𝐛𝐢 𝐇𝐚𝐧𝐧𝐚 𝐨𝐧 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧, 𝐇𝐞𝐫𝐢𝐭𝐚𝐠𝐞 & 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐩𝐚𝐜𝐭

𝐋𝐚𝐦𝐚𝐬𝐬𝐮 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐃𝐫. 𝐆𝐚𝐛𝐢 𝐇𝐚𝐧𝐧𝐚 𝐣𝐨𝐢𝐧𝐬 𝐓𝐡𝐞 𝐊𝐚𝐧𝐨 𝐓𝐚𝐥𝐤 𝐒𝐡𝐨𝐰 to share his inspiring journey as a distinguished Syrian-born Christian physician-scientist and entrepreneur. Dr. Hanna and Kano Suryoyo e.V. discuss:
🎓 His personal journey from Aleppo University Medical School to the US.
🔬The importance of translational research for real-world impact.
🏥 How Lamassu’s breakthrough therapies (SAYDI-53 & RABI-767) could change the future of cancer and pancreatitis treatment.
👨‍🔬 The values of service, excellence, and heritage that guide his work.

Watch the full interview on YouTube: https://youtu.be/dEPOKORjerU?si=f1W4evUQ63jiuCxb

06/27/2025

Lamassu Biotech has received a grant from the National Institutes of Health (NIH) to support its trials and advance the development of RABI-767, a novel therapeutic that could treat both humans and dogs suffering from the condition. With this NIH funding, Lamassu’s new Lamassu Pets division, in collaboration with The Ohio State University, will conduct clinical trials of RABI-767 in dogs in parallel with the ongoing Phase 2 human trials in partnership with Arrivo Bioventures. Learn more at LamassuPets.com.

06/26/2025

READ Lamassu CEO Gabi Hanna, MD's latest opinion column in Crain's Cleveland Business: "Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, and rising international competition. If we do not act to strengthen the United States’ biotech sector, we risk surrendering our global leadership to countries like China, which are aggressively scaling biotech industries without the same standards for safety and data accuracy."

Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, and rising international competition. If we do not act to strengthen the United States’ biot...

06/25/2025

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a shared mission to treat patients like family. Follow today using on LinkedIn, Facebook, Instagram and Twitter.

06/23/2025

It was a great week at I am Biotech's in Boston. Lamassu Biotech co-founders Gabi Hanna MD. and Greg Palmer, Ph.D., joined leadership from JobsOhio and the Ohio Life Sciences Association to talk about some of the company's exciting recent developments, including a major "One Health" grant the company received from the National Institutes of Health (NIH), Lamassu Pets' new collaboration with The Ohio State University, and the ongoing clinical trials for SA53, taking place at the Cleveland Clinic.



📸/ Tyler Allchin, JobsOhio

06/22/2025

With decades of experience developing leading medical treatments, Lamassu Biotech believes that it is not only the transformative power of science but also hope that leads to healing. To accelerate its drug development program, Lamassu fosters innovative, collaborative partnerships with a diverse range of distinguished partners. Learn more at www.lamassubiotech.com.

06/21/2025

𝐌𝐞𝐞𝐭 𝐋𝐚𝐦𝐚𝐬𝐬𝐮 𝐁𝐢𝐨𝐭𝐞𝐜𝐡’𝐬 𝐂𝐨-𝐅𝐨𝐮𝐧𝐝𝐞𝐫𝐬: Dr. Greg Palmer is co-founder and Chief Scientific Officer of Lamassu Biotech. He is a biomedical engineer by training with extensive experience in translational oncology research. He has led the development and translation of multiple drugs from early discovery through to clinical trials, most recently the development of RABI-767 through IND enabling studies, which is currently in a phase II clinical trial in humans and a canine clinical study, as well as SA53, which is in phase I/II trial in oncology.

Learn more at www.lamassubiotech.com.

06/20/2025

Lamassu Biotech is a privately held, clinical stage biopharmaceutical company developing an investigational MDM2 small molecule inhibitor (SA53). Learn more at LamassuBiotech.com.